Patient Feedback Surveys for Breast Cancer

Recruiting at 2 trial locations

Overseen By Sarah Tevis

Age: Any Age

Sex: Female

Trial Phase: Academic

Sponsor: University of Colorado, Denver

Disqualifiers: Male, Under 18, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 3 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 5

370 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Patient Reported Outcome Measure Survey, Lynparza for breast cancer?

The research suggests that using patient-reported outcome measures (PROMs) in cancer care can improve care processes, but there is no direct evidence that it improves patient outcomes like quality of life or satisfaction. However, feedback from PROMs might be associated with better care processes, which could indirectly benefit patients. ^{1 2 3 4 5}

Is the treatment generally safe for humans?

Patient-reported outcomes (PROs) are used in cancer trials to understand how patients feel and function during treatment, which can provide insights into safety. While specific safety data for Lynparza or similar treatments isn't detailed here, PROs help inform about potential side effects and overall patient well-being during cancer therapies. ^{3 4 6 7 8}

How does this treatment differ from other breast cancer treatments?

This treatment is unique because it focuses on collecting patient feedback through surveys to understand their quality of life and psychosocial outcomes, rather than directly treating the cancer itself. This approach helps tailor care to improve overall well-being and address specific needs of women with breast cancer. ^{4 9 10 11 12}

What is the purpose of this trial?

The purpose of this research protocol is to measure Patient Reported Outcome Measures (PROMs) in breast cancer patients. PROM results will be provided to patients and providers and the investigators will evaluate the relationship between patient engagement with PROM results and patient and clinicopathologic variables, utilization of supportive and hospital services, and patient satisfaction with patient-provider communication.

Research Team

Sarah Tevis

Principal Investigator

University of Colorado, Denver

Eligibility Criteria

This trial is for adult women (18 years or older) who have been diagnosed with breast cancer and are capable of completing surveys on their own. It's not suitable for anyone under 18, men, or patients unable to fill out surveys independently.

Inclusion Criteria

I have breast cancer.

Patients who can independently complete surveys

I am female.

Exclusion Criteria

Patients who cannot independently complete surveys

I am under 18 years old.

I am male.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Pre-operative

Patients receive pre-operative PROM surveys, with neoadjuvant chemotherapy patients receiving surveys every 3 months

Varies based on treatment plan

Multiple visits (in-person and virtual)

Post-operative

Post-operative PROM surveys administered at 2 weeks, 3 months, 6 months, 9 months, and 12 months after surgery

12 months

5 visits (in-person or virtual)

Follow-up

Annual PROM surveys conducted after the first year to monitor long-term outcomes

Long-term

Treatment Details

Interventions

• Patient Reported Outcome Measure Survey

Trial Overview The study focuses on measuring Patient Reported Outcome Measures (PROMs) in breast cancer patients. Feedback from these PROMs will be shared with both the patients and their healthcare providers to assess how it affects patient engagement, service use, and satisfaction with communication.

Participant Groups

Group I: Experimental Group Experimental Treatment 1 Intervention

Patients will receive the results from the PROM survey in graphical form each time they complete a survey.

Group II: Normative Control Active Control 1 Intervention

These patients will complete the PROM surveys, but will not be presented with the results of the survey.

Who Is Running the Clinical Trial?

University of Colorado, Denver

Lead Sponsor

Trials

1,842

Recruited

3,028,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Findings from Research

In a study involving 686 breast cancer patients, it was found that patient-reported outcome measures (PROMs) indicated higher rates of late toxicity compared to clinician assessments, suggesting that patients may experience more side effects than reported by their doctors.

Despite a low concordance rate of 58% between patient and clinician reports, PROMs can effectively identify patients with significant side effects, indicating that they could potentially replace in-person visits to outpatient clinics for follow-up care.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Are PROMs sufficient to record late outcome of breast cancer patients treated with radiotherapy? A comparison between patient and clinician reported outcome through an outpatient clinic after 10years of follow up. Brouwers, PJAM., van Loon, J., Houben, RMA., et al.[2018]

A systematic review identified five patient-reported outcome measures (PROMs) programs in routine cancer care across Europe, highlighting their dual purpose of monitoring individual patient outcomes and improving quality of care.

Despite the potential benefits of these PROM programs, critical issues such as costs, staff resources, and effective reporting methods were often overlooked in the studies, indicating areas for improvement in future implementations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Implementation of patient-reported outcome assessment in routine cancer care: A systematic review of multicentric programs in Europe. Scheibe, M., Herrmann, A., Schmitt, J., et al.[2022]

The review of six studies found that while patient-reported outcome measures (PROMs) are used in cancer clinics, their impact on improving patient outcomes like quality of life and satisfaction is limited, indicating a need for better implementation strategies.

Future interventions should focus on training healthcare professionals to effectively use PROM data, enhancing patient self-efficacy, and ensuring that PROMs are specific and interpretable, while future trials should adopt cluster-randomized designs to better control for contamination and link PROM use to patient outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Improving patient outcomes through the routine use of patient-reported data in cancer clinics: future directions. Luckett, T., Butow, PN., King, MT.[2022]

A study involving 171 Australian women with breast cancer found that both short and longer surveys assessing health-related quality of life (HrQoL) and psychosocial outcomes were well-received, with high completion rates and positive perceptions regarding their ease and relevance.

Participants expressed the need for more comprehensive questions addressing financial issues, emotional well-being, and treatment side effects, highlighting that while brevity in surveys is important, it should not compromise the assessment of significant outcomes for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A randomised online experimental study to compare responses to brief and extended surveys of health-related quality of life and psychosocial outcomes among women with breast cancer. Ettridge, K., Caruso, J., Roder, D., et al.[2022]

Patient-reported outcome measure (PROM) feedback interventions in oncology showed a positive impact on health-related quality of life (HRQL) and patient-healthcare provider communication, with a moderate effect size based on a meta-analysis of 29 studies involving 7071 cancer patients.

The intervention also demonstrated a significant improvement in 1-year overall survival rates, suggesting that providing feedback can enhance care processes and outcomes for cancer patients, although the findings are limited by a high risk of bias in the studies reviewed.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effectiveness of routine provision of feedback from patient-reported outcome measurements for cancer care improvement: a systematic review and meta-analysis. Lu, SC., Porter, I., Valderas, JM., et al.[2023]

Patient-reported outcomes (PROs) are increasingly important in randomized clinical trials for cancer, as they provide insights into how patients experience treatments, which cannot be captured by clinician reports alone.

The commentary highlights nine clinical trials where PROs significantly contributed to understanding treatment effects, demonstrating their value in guiding clinical practice, informing patients, and aiding health policy decisions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Listening to the Patient Voice Adds Value to Cancer Clinical Trials. Brundage, MD., Crossnohere, NL., O'Donnell, J., et al.[2023]

A study involving 2,245 cancer patients receiving chemotherapy revealed that 20% reported at least one severe toxicity, with significant variations in toxicity rates across different practices, ranging from 8% to 50%.

Commonly reported toxicities included pain and gastrointestinal issues, with 7% of patients requiring unplanned healthcare services, indicating that the severity and impact of side effects may be greater than previously documented in clinical trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Patient-reported outcomes collected in ambulatory oncology practices: Feasibility, patterns, and correlates. Friese, CR., Fauer, AJ., Kuisell, C., et al.[2021]

The study successfully collected patient-reported outcome measures (PROMs) from 2530 women with gynecologic malignancies, achieving a high completion rate of 78.1%, demonstrating that systematic collection of PROMs in a clinical setting is feasible.

Quality of life scores from this non-trial population were lower than those reported in clinical trials, suggesting that data from trials may not fully represent the experiences of routine patient populations, which is important for informed decision-making in treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Initial findings from a prospective, large scale patient reported outcomes program in patients with gynecologic malignancy. Sisodia, RC., Alimena, S., Ferris, W., et al.[2022]

Women with newly diagnosed early-stage breast cancer have significant information needs, and providing them with information can enhance their fighting spirit and reduce feelings of helplessness or hopelessness, based on a review of 537 participants across six studies.

While there is strong evidence that information interventions positively impact immediate emotional responses, the long-term effects on adjustment and well-being are less clear, and inadequate or conflicting information can lead to negative outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An exploration of the effects of information giving and information needs of women with newly diagnosed early-stage breast cancer: A mixed-method systematic review. Zou, G., Simons, A., Toland, S.[2022]

The Translational Breast Cancer Research Consortium identified 22 important domains and 52 measurement tools for assessing patient-reported outcomes in breast cancer trials, ensuring they are easily accessible and free of charge.

These selected measures have acceptable psychometric properties, making them reliable tools for evaluating the experiences and outcomes of patients in cancer research.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Patient-reported outcomes in the Translational Breast Cancer Research Consortium. Bowen, DJ., Shinn, EH., Gregrowski, S., et al.[2021]

A study involving 101 childhood cancer survivors, 101 parents, and 36 clinicians revealed significant differences in how these groups rated the importance of patient-reported outcomes (PROs) for survivorship care, highlighting the need for diverse perspectives in developing care tools.

Clinicians rated more items as important in the pain and fatigue domains compared to parents, while survivors placed greater importance on psychological stress and positive affect items, indicating that tailored approaches are necessary for effective survivorship care.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Importance ratings on patient-reported outcome items for survivorship care: comparison between pediatric cancer survivors, parents, and clinicians. Jones, CM., Baker, JN., Keesey, RM., et al.[2019]

A cross-sectional survey of 4992 cancer survivors in the UK showed that collecting patient-reported outcome measures (PROMs) is feasible, with a 66% response rate, indicating that this method can effectively assess quality of life (QoL) among survivors.

The study found that survivors from more deprived areas reported significantly lower QoL scores, and those with long-term conditions or recurrent disease also experienced poorer outcomes, highlighting the need for targeted support for these groups.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Patient-reported outcomes of cancer survivors in England 1-5 years after diagnosis: a cross-sectional survey. Glaser, AW., Fraser, LK., Corner, J., et al.[2022]

References

1. Ireland pubmed.ncbi.nlm.nih.gov

Are PROMs sufficient to record late outcome of breast cancer patients treated with radiotherapy? A comparison between patient and clinician reported outcome through an outpatient clinic after 10years of follow up. [2018]

2. Netherlands pubmed.ncbi.nlm.nih.gov

Implementation of patient-reported outcome assessment in routine cancer care: A systematic review of multicentric programs in Europe. [2022]

3. England pubmed.ncbi.nlm.nih.gov

Improving patient outcomes through the routine use of patient-reported data in cancer clinics: future directions. [2022]

4. Netherlands pubmed.ncbi.nlm.nih.gov

A randomised online experimental study to compare responses to brief and extended surveys of health-related quality of life and psychosocial outcomes among women with breast cancer. [2022]

5. Germany pubmed.ncbi.nlm.nih.gov

Effectiveness of routine provision of feedback from patient-reported outcome measurements for cancer care improvement: a systematic review and meta-analysis. [2023]

6. United States pubmed.ncbi.nlm.nih.gov

Listening to the Patient Voice Adds Value to Cancer Clinical Trials. [2023]

7. United States pubmed.ncbi.nlm.nih.gov

Patient-reported outcomes collected in ambulatory oncology practices: Feasibility, patterns, and correlates. [2021]

8. United States pubmed.ncbi.nlm.nih.gov

Initial findings from a prospective, large scale patient reported outcomes program in patients with gynecologic malignancy. [2022]

9. United States pubmed.ncbi.nlm.nih.gov

An exploration of the effects of information giving and information needs of women with newly diagnosed early-stage breast cancer: A mixed-method systematic review. [2022]

10. United States pubmed.ncbi.nlm.nih.gov

Patient-reported outcomes in the Translational Breast Cancer Research Consortium. [2021]

11. Netherlands pubmed.ncbi.nlm.nih.gov

Importance ratings on patient-reported outcome items for survivorship care: comparison between pediatric cancer survivors, parents, and clinicians. [2019]

12. England pubmed.ncbi.nlm.nih.gov

Patient-reported outcomes of cancer survivors in England 1-5 years after diagnosis: a cross-sectional survey. [2022]